Hideki Garren, MD, PhD, Chief Medical Officer at Prothena discusses data from two presentations at the Alzheimer’s Association International Conference (AAIC); PRX012, Prothena’s next generation anti-amyloid beta (Aβ) antibody and the dual Aβ-tau vaccine being developed for the prevention and treatment of Alzheimer’s Disease (AD). He talks about the company’s approach to addressing the AD global healthcare crisis.
Author: healthprofessionalradio
Achieve Life Sciences – Receives Grant for Cessation of Nicotine E-cigarette Use
Dr. Cindy Jacobs, PhD, MD, President and Chief Medical Officer at Achieve Life Sciences discusses the grant that was awarded from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH) to evaluate the use of cytisinicline as a treatment for the cessation of nicotine e-cigarette use.
3 Ways to Increase Productivity, Improve Patient Engagement and Reduce Burnout
Returning guest, Cathy Kuhn, PharmD, Director, Voice of the Customer at Updox, a complete healthcare communication platform for in-person and virtual care, discusses their recently released “Paperless Practice Playbook” with tips for providers on how to increase productivity, improve patient engagement and reduce burnout. She talks about why providers must eliminate paper in order to reduce the amount of time spent on administrative tasks for both provider and patients and how one practice saved more than 500 hours a year on administrative tasks by leveraging a paperless practice.
First Presentation of Long-Term Safety & Efficacy Data for Dengue Vaccine Candidate
Derek Wallace, Vice President and Dengue Global Program Lead at Takeda, discusses the first public presentation of long-term safety and efficacy results from the ongoing pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial of its dengue vaccine candidate, TAK-003, and the launch of the company’s global HCP dengue education platform, Dengue Academy.
Protodigm Uses AI to Suggest All Possible Avenues a Drug Could Go
Mike Rea, is founder of Protodigm, a contract skunkworks lab specializing in minimizing the risk of drug development by avoiding bias, premature specialization, and providing clients a universe of possibilities in which a drug could be brought to market. He talks about how the use of the skunkworks concept common in tech and engineering can innovate drug development.
Women’s Health – Uterine Fibroids and Heavy Menstrual Bleeding
As the most common type of non-cancerous tumors in women of reproductive age, uterine fibroids can cause physical symptoms, including heavy menstrual bleeding. Additionally, uterine fibroids can take a significant toll on quality of life, relationships and intimacy, employment, and create an overall reduced quality of well-being in a patient’s health. Dr. Veronica Gillispie-Bell, Senior Site Lead and Section Head of Obstetrics and Gynecology at Ochsner Kenner in New Orleans discusses heavy menstrual bleeding as a symptom of uterine fibroids, options in the treatment landscape, including ORIAHNN™, the first, non-surgical, oral medication developed specifically to treat heavy menstrual bleeding associated with uterine fibroids in premenopausal patients. She also shares how HCPs can open a dialogue with patients about their individual symptoms, lifestyle and treatment goals, and to address their concerns sooner rather than later.
Publication of Phase 3 STRATA2016 Study in Burns Peer Review Journal
Dr. Steve Romano, MD, Executive Vice President and Chief Scientific Officer at Mallinckrodt Pharmaceuticals discusses the results of their pivotal Phase 3 STRATA2016 clinical trial of StrataGraft ®, an allogeneic cellularized scaffold product for the treatment of adult patients with deep partial-thickness burns. The data was published in “Burns” peer review journal (August 2021). It received FDA approval in June 2021 and can provide burn surgeons with an alternative biologic treatment option for patients with deep partial-thickness burns.
Pulmonologist On Making Lung Cancer A Disease Of The Past
Nearly 1.8 million people globally die of lung cancer each year, more than the second and third most deadly cancers combined (colorectal and stomach cancer, respectively) because it is often detected and treated too late. Dr. Avrum “Avi” Spira, MD, MSc, Global Head of the Lung Cancer Initiative (LCI) at Johnson & Johnson, a renowned pulmonologist and lung cancer researcher, wants to make lung cancer a disease of the past. He discusses why early detection with lung cancer is key, what recent advancements in imaging, robotics and artificial intelligence have unlocked in new ways to screen for and access cancer, and how LCI is working to develop solutions to prevent, intercept and cure lung cancer.
Arrowhead Pharmaceuticals – New Positive Patient-Level Data In AATD Liver Disease
Dr. Chris Anzalone, PhD, President and CEO of Arrowhead Pharmaceuticals discusses new positive patient-level data from their AROAAT2002 global Phase 2 study of ARO-AAT, an RNA therapeutic being co-developed by the company and Takeda, in patients with liver disease caused by alpha-1 antitrypsin deficiency (AATD). He also talks about the company’s RNAi platform.
Horizon Therapeutics – First Patient In Phase 2 Systemic Lupus Erythematosus Study
Dr. Arezou Khosroshahi, MD, Associate Professor of Medicine at Emory University discusses the enrollment of the first patient in Horizon Therapeutics‘ Phase 2 trial to evaluate HZN-7734, a first- in-class, fully human monoclonal antibody to treat people with moderate to severely active systemic lupus erythematosus (SLE). SLE is an autoimmune disease where the immune system mistakenly attacks healthy cells and tissues. Of the 5 million people living with a form of lupus, SLE accounts for nearly 70 percent of cases and presents a tremendous unmet treatment need.